Open Access

Characterization of osteoarthritic human knees indicates potential sex differences

  • Qingfen Pan1,
  • Mary I. O’Connor2,
  • Richard D. Coutts3,
  • Sharon L. Hyzy4,
  • Rene Olivares-Navarrete4,
  • Zvi Schwartz4, 5 and
  • Barbara D. Boyan4, 6, 7Email author
Biology of Sex Differences20167:27

https://doi.org/10.1186/s13293-016-0080-z

Received: 17 February 2016

Accepted: 12 May 2016

Published: 2 June 2016

Abstract

Background

The prevalence of osteoarthritis is higher in women than in men in every age group, and overall prevalence increases with advancing age. Sex-specific differences in the properties of osteoarthritic joint tissues may permit the development of sex-specific therapies. Sex hormones regulate cartilage and bone development and homeostasis in a sex-dependent manner. Recent in vitro studies show that the vitamin D3 metabolite 1α,25-dihydroxyvitamin D3 [1α,25(OH)2D3] also has sex-specific effects on musculoskeletal cells, suggesting that vitamin D3 metabolites may play a role in osteoarthritis-related sex-specific differences. The purpose of this study was to determine if sex-specific differences exist in synovial fluid and knee tissues isolated from male and female patients with severe knee osteoarthritis. We determined the presence of vitamin D3 metabolites, inflammatory cytokines, growth factors, and matrix metalloproteinases (MMPs) in synovial fluid and assessed responses of articular chondrocytes and subchondral osteoblasts to 17β-estradiol, dihydrotestosterone, and 1α,25(OH)2D3.

Methods

Samples from knee joints of 10 Caucasian male and 10 Caucasian female patients with advanced osteoarthritis aged 65 to 75 years were obtained from total knee arthroplasty. Vitamin D metabolites, cytokines, MMPs, and growth factors in the synovial fluid were measured. Primary cultures of chondrocytes were isolated from fibrillated articular cartilage adjacent to osteoarthritis lesions and minimally affected cartilage distal to the lesion. Osteoblasts were isolated from the subchondral bone. Expression of receptors for 17β-estradiol and 1α,25(OH)2D3 was assessed by real-time PCR. Chondrocytes and osteoblasts were treated with 10−8 M 17β-estradiol, dihydrotestosterone, or 1α,25(OH)2D3 and effects on gene expression and protein synthesis determined.

Results

Histology of the articular cartilage confirmed advanced osteoarthritis. Sex differences were found in synovial fluid levels of vitamin D metabolites, cytokines, and metalloproteinases as well as in the cellular expression of receptors for 17β-estradiol and 1α,25(OH)2D3. Male cells were more responsive to 1α,25(OH)2D3 and dihydrotestosterone, whereas 17β-estradiol-affected female cells.

Conclusions

These results demonstrate that there are underlying sex differences in knee tissues affected by osteoarthritis. Our findings do not address osteoarthritis etiology but have implications for different prevention methods and treatments for men and women. Further research is needed to better understand these sex-based differences.

Keywords

Osteoarthritis Chondrocytes Osteoblasts Estrogen Testosterone Dihydrotestosterone 1α,25(OH)2D3 24R,25(OH)2D3 Vitamin D

Background

Osteoarthritis (OA) is a leading cause of pain and disability in adults. Nearly one in two people may develop symptomatic knee OA by age 85 [1]. OA affects the whole joint, including the articular cartilage, subchondral bone, muscle, tendons, meniscus, and synovium, and impacts daily life and function. Symptoms may include joint pain, tenderness, stiffness, and locking [2]. A variety of causes, including hereditary, developmental, metabolic, and mechanical deficits, may initiate processes leading to cartilage loss. Risk factors for developing OA include patient sex, race/ethnicity, joint instability, obesity, joint trauma, and age. Epidemiologic studies show sex-specific differences in the prevalence and severity of OA [3, 4]. On average, the rate of arthritis is 58 % higher in women than in men [5]. Women report more pain due to OA than men report and are more likely to have reductions in function and quality of life [6]. Biomechanical differences between men and women may contribute to differences in OA prevalence, although data supporting this are not clear [7]; thus, other sex differences may be involved.

Sex hormones are important regulators of cartilage biology. Ovariectomized Cynomolgus monkeys exhibit histopathologic features typical of OA, suggesting that estrogen has a protective effect [8]. Studies using a mouse model of OA support this; ovariectomized female mice had more OA than intact mice, but orchidectomized male mice had less severe OA than intact males [9]. A number of studies have shown sexual dimorphism in the response of chondrocytes and osteoblasts to 17β-estradiol (E2) and dihydrotestosterone (DHT) at the cellular level [1012]; however, the effects of sex hormones on the incidence and progression of OA of the knee, as well as on the regenerative potential of affected cartilage, are poorly understood.

Studies indicate that bone and cartilage cells exhibit sex-specific responses to the vitamin D metabolites 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3] and 24R,25-dihydroxyvitamin D3 [24,25(OH)2D3] [1315]. In addition to its role in maintaining calcium homeostasis and bone metabolism [1618], recent evidence suggests that 1,25(OH)2D3 plays important roles in cartilage remodeling and participates in the inflammatory response [19, 20]. Epidemiologic studies have correlated low serum levels of 25-hydroxyvitamin D3 [25(OH)D3], the precursor of 1,25(OH)2D3 and 24,25(OH)2D3, with OA progression [21]. Moreover, vitamin D supplementation had a protective effect against OA in rats by reducing messenger RNAs (mRNAs) for matrix metalloproteinase (MMP)-3, interleukin-1β (IL1β), and tumor necrosis factor alpha (TNFα), factors associated with cartilage degradation and inflammation [22]. Interestingly, 1α,25(OH)2D3 induced production of E2 in female rat chondrocytes but not in male chondrocytes, further demonstrating that there is sexual dimorphism at the cellular level [23].

As a first step in understanding how sex differences might have an impact on OA, we investigated whether differences were present in patients with OA sufficiently severe to warrant total joint replacement. We reasoned that the disease was comparable in patients of both sexes, and while the etiology of the disease in any one patient was unknown, all patients would receive the same treatment. Thus, identified differences would be more likely to be intrinsic to the sex of the patient, rather than random non-specific observations. We examined serum and synovial fluid obtained at the time of surgery as well as the morphology of the articular cartilage. Also, we isolated chondrocytes and osteoblasts and examined their responses to 1α,25(OH)2D3, E2, and DHT.

Methods

Patient population

Surgeries and preclinical assessments were performed at Mayo Clinic, Jacksonville, FL, USA. Bench studies were conducted at Georgia Institute of Technology, Atlanta, GA, USA, and Virginia Commonwealth University, Richmond, VA, USA. Analyses for the studies were performed at all locations listed under affiliations. Each author certifies that his or her institution approved the human protocol for this investigation (Mayo Clinic - 11-001468; Georgia Tech - H11239; VCU - HM15270), and that all investigations were conducted in conformity with ethical principles of research, and that informed consent for participation in the study was obtained.

Twenty white, non-Hispanic patients (10 men/10 women) between the ages of 65 and 75 years, who were undergoing total knee arthroplasty (TKA) due to severe OA of the knee, were included in our study. Patients with inflammatory arthritis, osteonecrosis, prior upper tibial osteotomy, premenopausal women, patients aged less than 65 years or aged greater than 75 years; who were insulin-dependent or diabetic, with a BMI greater than 30 kg/m2, or history of knee infection were excluded from our study (Table 1). The study size of 20 was powered based on serum 25(OH)D3 levels, given an alpha of 0.05, a standard deviation of 17, an effect size of 22.5, and power of 0.8.
Table 1

Patient demographics and clinical history

Variable

Female

Male

p valuea

Median age (IQR) - years

70 (68, 71)

69 (66, 72)

0.42

Median body mass index (IQR) - kg/m2

26.2 (25.6, 28.1)

27.0 (24.3, 28.6)

0.34

Vitamin D use - no. (%)b

  

0.14

 Currently

6 (60 %)

3 (30 %)

 

 Previously

3 (30 %)

2 (20 %)

 

 Never

1 (10 %)

5 (50 %)

 

Median 25-hydroxy D3 (IQR) - ng/ml

42.1 (33.7, 47.2)

38.4 (31.0, 52.6)

0.79

Bisphosphonates use - no. (%)b

  

0.47

 Previously

2 (20 %)

0 (0 %)

 

 Never

8 (80 %)

10 (100 %)

 

Estrogen use - no. (%)b

  

<0.001

 Currently

4 (40 %)

0 (0 %)

 

 Previously

4 (40 %)

0 (0 %)

 

 Never

2 (20 %)

10 (100 %)

 

Previously injured a knee so badly it was difficult to walk for at least a week - no. (%)

0 (0 %)

3 (30 %)

0.21

Prior knee surgery - no. (%)

6 (60 %)

6 (60 %)

1.00

Prior intra-articular injections of steroids - no. (%)

7 (70 %)

5 (50 %)

0.65

Median no. of steroid injections (IQR)

1 (0, 1)c

1 (0, 3)

0.58

Prior intra-articular injection of hyaluronic acid - no. (%)

3 (30 %)

5 (50 %)

0.65

Median no. of hyaluronic injections (IQR)

0 (0, 1)

2 (0, 3)

0.30

Knee to be replaced - no. (%)

  

1.00

 Right

6 (60 %)

6 (60 %)

 

 Left

4 (40 %)

4 (40 %)

 

IQR interquartile range

a p values result from a Wilcoxon rank sum test for numerical variables and Fisher’s exact test for categorical variables

b p values are based on categorization as currently or previously used vs. never used

cInformation was not available for 1 patient

Information collected at the Mayo Clinic before surgery included patient demographics (age, sex, body mass index [BMI]) and medication and supplement use (vitamin D supplements, bisphosphonates, and estrogen). In addition, we used several rating scales to provide baseline information on the two patient cohorts in the event that sex differences were observed. These included the Short Form-12 (SF-12) Health Survey, the Western Ontario & McMaster Universities Arthritis Index (WOMAC), and the Physical Activity Scale for the Elderly (PASE) functional scale tests. Serum 25(OH)D3 levels and standard radiographs were obtained for each patient. Within 2 weeks of surgery, patients completed the Osteoarthritis Research Society International-Outcome Measures in Rheumatology (OARSI-OMERACT) pain scale [24], the knee pain map [25], and pressure–pain thresholds at the knee using JTECH Tracker wireless software (V.5; JTECH Medical, Midvale, UT, USA) [26, 27].

Although not statistically significant, there was some evidence to suggest that previous or current vitamin D use was more common in women patients than in men patients (90 vs. 50 %; p = 0.14). As expected, only the female cohort reported previous or current estrogen use (80 vs. 0 %; p < 0.001). There was no evidence of a difference in age, BMI, bisphosphonate use, prior knee surgery, prior intraarticular steroid injections, or prior intraarticular hyaluronic acid injections between men and women patients (p ≥ 0.21).

Per preoperative radiographic and knee pain assessments, the pain-pressure threshold 1 cm above the medial joint line was lower in women than men (median, 3.0 vs. 5.1 kg; p = 0.007) (Table 2). There was no evidence of a difference in patient serum levels of 25(OH)D3, radiographic assessment, knee pain, or areas of knee pain (p ≥ 0.37). There was no evidence of a difference between male and female patients in the pain and functional assessments before surgery, including the WOMAC, OARSI-OMERACT, and SF-12 (p ≥ 0.36) (Table 3).
Table 2

Preoperative knee pain and radiographic assessment

Variable

Female

Male

p valuea

Radiographic assessment

   

 Kellgren-Lawrence Grading Scale - no. (%)

  

0.37

  Grade 3

1 (10 %)

0 (0 %)

 

  Grade 4

9 (90 %)

10 (100 %)

 

Median pain-pressure threshold (IQR) - kg

   

 Medial joint line

4.5 (3.7, 5.1)

5.3 (4.1, 6.9)

0.16

 1 cm above the medial joint line

3.0 (2.7, 3.8)

5.1 (4.5, 6.2)

0.007

 1 cm below the medial joint line

4.0 (3.5, 4.1)

5.6 (4.0, 6.8)

0.10

Area(s) of knee pain - no. (%)b

   

 Localized

   

  Superior lateral

0 (0 %)

1 (10 %)

1.00

  Patella

0 (0 %)

1 (10 %)

1.00

  Medial joint line

3 (30 %)

2 (20 %)

1.00

  Inferior lateral

1 (10 %)

0 (0 %)

1.00

  Inferior medial

1 (10 %)

0 (0 %)

1.00

 Regional

   

  Medial

1 (10 %)

1 (10 %)

1.00

  Patella

1 (10 %)

2 (20 %)

1.00

 Diffuse pain

4 (40 %)

3 (30 %)

1.00

a p values result from a Wilcoxon rank sum test for numerical variables and Fisher’s exact test for categorical variables

bMore than one location per patient was possible. Pain was not reported at any of the following locations: superior medial, lateral joint line, back of knee, lateral (regional), and back of knee (regional)

Table 3

Pain and functional assessment prior to surgery

Variable

Female

Male

p valuea

WOMAC

   

 Median total raw score (IQR)

39 (32, 47)

45 (27, 55)

0.76

 Median pain score (IQR)

8.5 (7, 10)

9.0 (5, 12)

0.73

 Median stiffness score (IQR)

4.0 (2, 5)

4.0 (3, 6)

0.64

 Median difficulty performing daily activities score (IQR)

28 (21, 33)

32 (18, 38)

0.70

OARSI-OMERACT pain scale

   

 Median total pain score (IQR)

49 (30, 59)

42 (39, 61)

0.88

 Median constant pain subscore (IQR)

45 (20, 55)

38 (25, 45)

0.36

 Median intermittent pain subscore (IQR)

48 (42, 63)

50 (42, 67)

0.70

SF-12

   

 Median physical scale (IQR)

33 (29, 42)b

38 (30, 39)

0.55

 Median mental scale (IQR)

61 (54, 63)b

57 (54, 66)

0.90

a p values result from a Wilcoxon rank sum test

bInformation was not available for 1 patient

All patients exhibited similar morphologic and histological features. All patients had radiographic evidence of joint narrowing and bone-bone contact (Fig. 1a).
Fig. 1

Gross changes in osteoarthritic joints. a Radiograph showing joint narrowing and bone-to-bone contact. b Articular cartilage showing areas of minimal fibrillation (arrow) and areas of maximum erosion (star). c Safranin-O-stained fibrillated cartilage showing loss of proteoglycan

Sample collection

Fresh human tissue was obtained from consenting patients undergoing elective TKA at Mayo Clinic, Jacksonville, FL, USA. Synovial fluid was aspirated from the knee joint prior to skin incision, snap frozen, and stored at −80 °C. Bone, with overlaying cartilage specimens from the distal and posterior medial and lateral femoral condyles, and the proximal tibial bone cut were also obtained. Bone/cartilage specimens were shipped, on ice, to the Institute for Bioengineering and Bioscience at the Georgia Institute of Technology (Atlanta, GA, USA) or the School of Engineering, Institute for Engineering and Medicine at Virginia Commonwealth University (VCU; Richmond, VA, USA). Upon receipt, knee tissues were dissected, separating articular cartilage, subchondral bone, synovial membrane, and meniscus. Tissues were coded using de-identified patient numbers provided by Mayo Clinic. Articulating surfaces of the tibia and femur were photographed. Chondrocytes and osteoblasts were isolated at the time of receipt; meniscus, synovium, bone, and cartilage were processed for histology. Synovial fluid was thawed and aliquoted, then stored at −80 °C until used. All assays performed at VCU were blinded to donor sex.

Histology

Following fixation in 10 % formalin, cartilage was decalcified (Decal Chemical Corporation, Tallman, NY, USA) for 16 h on a rotating platform before undergoing dehydration in a series of 95 and 100 % ethanol and xylene washes. Samples were embedded in paraffin; 7-μm sections were stained with safranin-O to assess glycosaminoglycan content.

Synovial fluid

Synovial fluid levels of 1,25(OH)2D3 were measured according to manufacturer’s instructions using a human 1,25(OH)2D3 ELISA kit (DHVD3, Novatein Biosciences, Cambridge, MA, USA). Levels of 25(OH)D3 were measured according to manufacturer’s instructions using a human 25-hydroxyvitamin D3 ELISA kit (25HVD3, Novatein Biosciences). In addition, we used an ELISA kit from Immunodiagnostic Systems (Gaithersburg, MD, USA) that measured 25(OH)D3, 25(OH)D2, and 24,25(OH)2D3. We then approximated the amount of 24,25(OH)2D3 plus 25(OH)D2 by subtracting the values for 25(OH)D3 that had been obtained using the Novatein Biosciences assay. Because other vitamin D metabolites might have also been present, including 1,24,25(OH)3D3, mass spectrometry (Thermo Vantage Triple Quadrupole Mass Spectrometer; Biotrial, Quebec, Canada) was used to measure 24,25(OH)2D3 specifically. Data were calculated per milliliter of synovial fluid.

Inflammatory cytokines and MMPs present in the synovial fluid were measured using a Luminex screening assay (R&D Systems, Minneapolis, MN, USA). This assay uses superparamagnetic beads coated with analyte-specific antibodies. Transforming growth factor beta-1 (TGFβ1), TGFβ2, and TGFβ3 levels were measured using a magnetic bead-based multiplex assay (Bio-Rad, Hercules, CA, USA). Sulfated glycosaminoglycan levels were measured using the dimethyl methylene blue assay (Sigma-Aldrich, St. Louis, MO, USA) [28]. In all cases, data were determined per milliliter of synovial fluid.

Chondrocyte cultures

Articular cartilage was harvested by sharp dissection from areas of minimal fibrillation and areas of maximum erosion (Fig. 1b). Cartilage pieces were minced and incubated in Dulbecco’s modified Eagle’s medium (DMEM; Thermo Fisher, Waltham, MA, USA) containing 0.25 % trypsin (Life Technologies, Carlsbad, CA, USA) for 30 min at 37 ° C. After discarding the trypsin digest, chondrocytes were isolated from cleaned cartilage fragments by incubating them for 16 h in 0.03 % type-II collagenase (Worthington Biosciences, Lakewood, NJ, USA) in DMEM containing 100 U/mL penicillin and 100 μg/mL streptomycin. Cells were separated from remaining cartilage pieces by straining the mixture through a 40-μm filter. Cells were cultured in DMEM supplemented with 10 % fetal bovine serum (Life Technologies) and 100 U/mL penicillin and 100 μg/mL streptomycin. A preliminary study demonstrated that first-passage cells retained their chondrocyte phenotype, whereas cells at later passages did not. Therefore, passage 1 cells were used for all experiments and cells were seeded at 15,000/cm2 for all experiments. We have successfully identified differences at the cellular level with as few as three donors per group [29], but we opted to culture the cells from all 20 patients. Unfortunately, there was not sufficient tissue available in some cases; in other instances, cell growth was inadequate. The final sample size for the cell culture studies was 6 males and 6 females.

In order to determine if chondrocytes were competent to respond to hormone treatment, mRNA levels for receptors for 1,25(OH)2D3 (vitamin D receptor [VDR] and protein disulfide isomerase A3 [PDIA3]) or E2 (ERα66 [ESR1] and ERα36) were measured in chondrocytes from both fibrillated and minimally affected OA tissues via real-time qPCR [30]. The cells were further characterized with respect to basal expression of inflammatory cytokines (IL1A, IL1B, IL6, IL8, and IL10) [31]. Related work has shown that differentiation of chondrocytes in response to 1,25(OH)2D3 involves signaling via wingless-Int pathway molecules (WNT3A, WNT5A, CTNNB, DKK1, and DKK2) [32]; therefore, we also measured RNA expression for these proteins. Primers for each of the mRNAs are shown in Additional file 1: Table S1.

RNA was harvested using a TRIzol (Invitrogen, Carlsbad, CA, USA) extraction method following manufacturer’s protocol. RNA was quantified using a NanoDrop spectrophotometer (Thermo Scientific, Waltham, MA, USA) and specific mRNAs (250 ng) were amplified using reverse transcription (High-Capacity cDNA Reverse Transcription Kit; Life Technologies). Starting quantities of mRNA were determined using SybrGreen chemistry (Power SYBR; Green PCR Master Mix, Life Technologies) in a StepOne Plus imaging system (Life Technologies). All gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

In order to examine if there were sex differences in response to hormonal treatment, confluent first passage chondrocytes were treated with 10−8 M 1α,25(OH)2D3 (Enzo Life Sciences, Plymouth, PA, USA) or 10−8 M E2 (Sigma-Aldrich, St. Louis, MO, USA). In addition, cells were treated with 10−7M 24R,25(OH)2D3 (Enzo Life Sciences) or 10−8 M 5α-DHT (Sigma-Aldrich). mRNAs for aggrecan (ACAN), type-II collagen (COL2A1), and cartilage oligomeric matrix protein (COMP) were measured at 12 h using real-time qPCR. Primers used are listed in Additional file 1: Table S1.

To measure alkaline phosphatase specific activity, confluent first-passage cells were treated for 24 h with either vehicle (0.01 % ethanol), or 10−8 M 1α,25(OH)2D3 or E2. Cells were harvested by trypsin digestion and were lysed in Triton X-100 (Sigma-Aldrich). Enzyme activity was measured by assaying the release of p-nitrophenol from p-nitrophenylphosphate at a pH of 10.2 in the cell lysates and was normalized to total protein content of the cell lysates (BCA Protein Assay; Thermo Fisher Scientific, Waltham, MA, USA) [33].

Osteoblast cultures

Subchondral bone samples obtained from regions under minimally fibrillated cartilage and regions of maximal cartilage erosion were minced into small chips, incubated with 0.25 % trypsin for 30 min at 37 °C, and then washed with DMEM with 1 % penicillin-streptomycin three times. After washing, bone chips were cultured for 2 weeks in Petri dishes containing DMEM with 1 % penicillin-streptomycin and 10 % fetal bovine serum to enable osteoprogenitor cells to migrate out onto the dish surface. Media were changed once a week until cells reached confluence. Cells were then subcultured by seeding at 10,000 cells/cm2 for all experiments.

The presence of receptors for 1α,25(OH)2D3 and E2 was assessed as described for the chondrocyte cultures above. Response to the hormones was examined using confluent first-passage osteoblasts treated with either vehicle (0.01 % ethanol) or 10−8 M 1α,25(OH)2D3, E2 or DHT for 24 h. The conditioned media were collected, and levels of secreted osteocalcin and osteoprotegerin were determined. Osteocalcin was measured using a commercially available radioimmunoassay following manufacturer’s instructions (Biomedical Technologies, Stoughton, MA, USA) [34]. Osteoprotegerin was measured by ELISA (R&D Systems, Minneapolis, MN, USA) [35]. After decanting the conditioned media, cells were harvested by trypsin digestion and alkaline phosphatase-specific activity was determined in cell lysates. DNA was measured using a fluorometric assay from Promega (Madison, WI, USA). Levels of secreted factors in the conditioned media were normalized to total DNA.

Statistical analysis

Clinical data were summarized for each sex by the sample median and interquartile (IQR) range for numerical variables whereas categorical variables were summarized by frequency and percentage. Comparisons between men and women were evaluated using a Wilcoxon rank sum test for numerical variables, Cochran-Armitage test for trend for ordered variables, and Fisher exact test for categoric variables. Statistical significance was considered at p < 0.05 without adjustment for multiple testing, owing to the exploratory and hypothesis-generating nature of the study. The considerable number of tests performed increased the chance of a type-I error, and interpretation of study results should consider this. Additionally, the small sample size increased the chance of a type-II error (i.e., false-negative association). Statistical analyses were performed using SAS statistical software (V. 9.3; SAS Institute Inc.; Cary, NC, USA).

Data from the cell studies are presented as the mean ± standard error (SEM) of six independent cultures for each patient per variable. Six patients of each sex were examined for the cell-hormone treatment study. Statistical significance was determined by ANOVA with post hoc Bonferroni modification of Student’s t test. For graphs labeled as treatment over control, the value of each sample from the treated group was divided by the mean of the control group. Each data point represents the mean ± SEM for six normalized values. The control is represented by a dashed line with a value equal to 1. Significance was determined by using the Mann-Whitney test. Significance was reached when p value was less than 0.05.

Results

Histology

Histology confirmed the radiographic diagnosis of severe OA. The articular cartilage was fibrillated and exhibited marked loss of sulfated glycosaminoglycans (sGAGs) (Fig. 1c).

Synovial fluid

Synovial fluid composition differed between men and women patients (Table 4). Men had increased levels of MMPs 1, 7, 9, and 13. Hepatocyte growth factor (HGF), stem cell factor (SCF), and stem cell growth factor beta (SCGFβ) were all higher in male synovial fluid than in the synovial fluid of women patients. The amounts of sGAG, TGFβ1, and TGFβ2 were higher in men compared with women. Women had higher levels of inflammatory cytokines, IL2α, IL3, IL12p40, IL16, IL18, and TNFβ, and chondrocyte apoptosis-inducing factor (TRAIL) compared with men. Higher levels of macrophage stimulators (leukemia inhibitory factor [LIF], macrophage colony-stimulating factor [M-CSF], macrophage migration inhibitory factor [MIF]), and pro-inflammatory mediators (growth-regulated oncogene α [GRO-α], monocyte chemotactic protein-3 [MCP-3], and monokine induced by gamma interferon [MIG]) were found in women compared with men.
Table 4

Levels of inflammatory cytokines measured in synovial fluid

 

Mean value (pg/ml) ± SEM

  
 

Male

Female

p value

 

HGF

1075.00 ± 254.20

514.30 ± 46.10

0.0352

Males > females

IFN-α2

279.30 ± 50.09

159.80 ± 12.10

0.0207

IL1α

389.00 ± 23.91

337.40 ± 9.80

0.0367

MMP-1

2219.00 ± 539.60

1270.00 ± 84.74

0.049

MMP-2

1981.00 ± 50.44

1811.00 ± 42.84

0.0248

MMP-7

1189.00 ± 15.21

1147.00 ± 7.63

0.0173

MMP-9

1565.00 ± 473.20

585.60 ± 135.50

0.0328

MMP-12

39.20 ± 0.87

36.90 ± 0.46

0.0227

MMP-13

441.90 ± 18.22

396.00 ± 7.241

0.0187

SCF

478.00 ± 116.2

239.80 ± 21.45

0.0487

SCGF-β

5503.00 ± 1713.20

1928.00 ± 433.60

0.0487

TGFβ1

1723.00 ± 282.00

1070.00 ± 109.00

0.0464

TGFβ2

35.79 ± 4.72

23.69 ± 2.74

0.0415

sGAG

14.04 ± 2.02

6.25 ± 0.57

0.004

GRO-α

459.40 ± 95.18

739.80 ± 61.36

0.0217

Females > males

IL2α

843.90 ± 166.50

1321.00 ± 120.20

0.0306

IL3

806.90 ± 204.80

1289.00 ± 55.29

0.0395

IL12p40

380.60 ± 81.14

578.20 ± 26.41

0.0342

IL16

708.10 ± 148.50

1353.00 ± 247.00

0.0449

LIF

309.60 ± 60.31

480.80 ± 41.60

0.0294

MCP-3

147.70 ± 29.88

220.10 ± 17.42

0.0466

M-CSF

748.80 ± 161.60

1156.00 ± 107.00

0.0468

MIF

752.60 ± 172.70

1665.00 ± 357.50

0.0323

MIG

1793.00 ± 321.80

4252.00 ± 1018.00

0.0371

TNF-β

148.00 ± 42.95

252.20 ± 8.99

0.0304

TRAIL

714.90 ± 156.20

1100.00 ± 79.97

0.0332

β-NGF

5.67 ± 2.76

3.42 ± 0.83

0.4791

Not significant

CTACK

613.00 ± 112.90

925.30 ± 172.90

0.1621

IL18

156.80 ± 8.56

160.90 ± 7.90

0.727

IL1β

214.70 ± 99.25

128.80 ± 13.42

0.4113

MMP-3

2898.00 ± 81.25

2961.00 ± 100.4

0.6544

MMP-8

1183.00 ± 310.20

985.50 ± 103.40

0.4934

SDF-1α

506.50 ± 79.08

461.70 ± 51.30

0.6259

No sex-specific differences in the concentration of 1,25(OH)2D3 in synovial fluid were detected (Fig. 2a). Compared to men, women had less 25(OH)D3; 25(OH)D3 + 25(OH)D2 + 24,25(OH)2D3; and calculated 24,25(OH)2D3 + 25(OH)D2 in the synovial fluid (Fig. 2b–d); however, mass spectroscopy detected no differences in the levels of 24,25(OH)2D3 between women and men (Fig. 2e).
Fig. 2

Vitamin D metabolites in synovial fluid. ad Levels of vitamin D metabolites in the synovial fluid of 10 males and 10 females undergoing total joint arthroplasty were measured using ELISA and (e) mass spectrometry. * p < 0.05 compared with male

Chondrocyte cultures

Chondrocytes expressed mRNAs for both receptors for 1,25(OH)2D3 (nVDR and PDIA3) and for ERα66 (ESR1) and ERα36 (Fig. 3a–d, respectively). Female chondrocytes from minimally fibrillated cartilage had less VDR mRNA than male cells but comparable levels of mRNAs for the other three receptors. Female cells isolated from eroded cartilage had less nVDR mRNA, less PDIA3 mRNA, and more ESR1 mRNA than male cells.
Fig. 3

Phenotypic characteristics of female and male primary chondrocytes isolated from osteoarthritic knees. Primary chondrocytes were isolated from minimally fibrillated or eroded cartilage surfaces. mRNAs for 1α,25(OH)2D3 (VDR (a) and PDIA3 (b)); estrogen receptors (ERα66 (c) and ERα36 (d)); interleukins (IL1A (e), IL1B (f), IL6 (g), IL8 (h), and IL10 (i)); and WNT signaling molecules (WNT3A (j), WNT5A (k), β-catenin [CTNNB] (l), DKK1 (m), and DKK2 (n)) were measured using real-time qPCR. Data are the mean levels from 6 males and 6 females. * p < 0.05 compared with minimal fibrillation; p < 0.05 compared with male

mRNAs for inflammatory cytokines were elevated in male cells from eroded cartilage compared to cells from minimally fibrillated cartilage (Fig. 3e–h). In contrast, female cells exhibited no differences in IL1A or IL1B mRNAs and expression of IL6 and IL8 was reduced in the female erosion cells compared with the minimally fibrillated cells. Female cells from minimally fibrillated cartilage had higher expression of IL1A, IL6, and IL8 than male cells from similar cartilage. No difference in expression of the anti-inflammatory cytokine IL10 was evident between male and female cells or as a function of the type of cartilage from which the cells were isolated (Fig. 3i).

Sex-specific differences in expression of WNT signaling molecules were observed, particularly in chondrocytes isolated from erosion cartilage. WNT3A, CTNNB, DKK2, and DKK2 were all expressed to a greater extent in male erosion cells than in cells from minimally eroded tissues (Fig. 3j, l–n). This was also the case for CTNNB and DKK1 in cells from female erosion tissue compared with minimally fibrillated female cells (Fig. 3l, m). However, WNT5A (Fig. 3k) and DKK2 (Fig. 3n) were reduced in female erosion tissue compared with minimally fibrillated tissue, and the levels of these two mRNAs were significantly lower than seen in male cells from similar tissues.

Chondrocytes responded to stimulation by vitamin D metabolites in a sex-specific manner. Male cells exhibited a more robust increase in alkaline phosphatase activity in response to 1α,25(OH)2D3 than female cells (Fig. 4a), but expression of ACAN was reduced (Fig. 4b). No sex-specific differences in expression of COL2A1 or COMP were observed (Fig. 4c, d). 24R,25(OH)2D3 inhibited alkaline phosphatase activity in female chondrocyte cultures compared with control cells and compared with male cells (Additional file 2: Figure S1A). 24R,25(OH)2D3 had a stimulatory effect on male cells compared with control cultures and to female cells treated with the vitamin D metabolite (Additional file 2: Figure S1B). 24R,25(OH)2D3 affected male and female cells comparably with respect to COL2A1 (increase) or COMP (decrease) (Additional file 2: Figure S1C, D).
Fig. 4

Phenotypic characteristics of female and male chondrocytes isolated from osteoarthritic knees. ad Passage 1 chondrocytes were treated with 10−8 M 1α,25(OH)2D3 or 10−8 M E2. eh Alkaline phosphatase specific activity (a, e) was measured in whole cell lysates. mRNAs for chondrocyte genes aggrecan (b, f), type-II collagen (c, g), and cartilage oligomatric matrix protein (d, h) were measured using real-time qPCR. Data show treatment versus vehicle control ratios of 6 male and 6 female donors. The dashed line represents the vehicle control (dashed line = 1). * p < 0.05 vs. control; p < 0.05 vs. male

E2 reduced alkaline phosphatase activity in male chondrocytes and stimulated it in female cells (Fig. 4e). E2 had no effect on expression of ACAN, COL2A1, or COMP in male cells, but it increased expression of all three mRNAs in female cells (Fig. 4f–h). DHT reduced alkaline phosphatase activity in male cells but had no effect on the enzyme in female cells (Additional file 2: Figure S1E). DHT had no effect on expression of ACAN, COL2A1, or COMP in cells of either sex (Additional file 2: Figure S1F–H).

Osteoblast cultures

Male osteoblasts from erosion tissue expressed high levels of nVDR compared with minimally fibrillated male cells or with female cells from either site (Fig. 5a). No differences in expression of PDIA3 were observed (Fig. 5b). Female erosion cells expressed more ESR1 (ERα) and female minimally fibrillated osteoblasts expressed more ERα36 than male cells (Fig. 5c, d); however, no differences in expression of either E2 receptor were seen as a function of the tissue source for either males or females.
Fig. 5

Phenotypic characteristics of female and male primary osteoblasts isolated from osteoarthritic knees. Female and male primary osteoblasts were isolated from subchondral bone. mRNAs for 1α,25(OH)2D3 (VDR (a) and PDIA3 (b)) and estrogen receptors ERα66 (ERα (c)) and ERα36 (d) were measured using real-time qPCR. Data are the mean ± SEM of 6 males and 6 females. * p < 0.05 vs. minimal fibrillation; p < 0.05 vs. male

In male osteoblasts, 1α,25(OH)2D3, increased alkaline phosphatase activity (Fig. 6a) and osteocalcin production (Fig. 6b) but decreased levels of osteoprotegerin (Fig. 6c). 1α,25(OH)2D3 had no effect on alkaline phosphatase activity in female cells, but its stimulatory effect on osteocalcin and inhibitory effect on osteoprotegerin were comparable to that seen in male cells. E2 inhibited alkaline phosphatase activity in male cells (Fig. 6d). It had no effect on enzyme activity in female osteoblast, but it stimulated osteocalcin production in the female cells (Fig. 6e), and it inhibited osteoprotegerin production (Fig. 6f). In contrast, DHT increased alkaline phosphatase activity in male osteoblasts (Additional file 3: Figure S2A), increased osteocalcin production (Additional file 3: Figure S2B), and reduced osteoprotegerin production (Additional file 3: Figure S2C). Female cells exhibited increased osteoprotegerin production in response to DHT.
Fig. 6

Phenotypic characteristics of female and male primary osteoblasts isolated from osteoarthritic knees. First-passage osteoblasts were treated with 10−8 M 1α,25(OH)2D3 (ac) or 10−8 M E2 (df). Alkaline phosphatase-specific activity was measured in whole cell lysates (a, d). Protein levels of osteocalcin (b, e) and osteoprotegerin (c, f) were measured in conditioned media. Data show treatment compared with vehicle control ratios of the responses of 6 male and 6 female patients. The dashed line represents the vehicle control (dashed line = 1). * p < 0.05 vs. control; p < 0.05 vs. male

Discussion

Rather than investigating an underlying sex-dependent mechanism in the etiology of OA, the goal of this study was to screen a broad range of variables in tissues and fluids obtained during TKA to investigate whether there are sex differences in knee tissues affected by OA. The severity of OA in men and women study patients was comparable. Thus, detected differences could be ascribed to underlying sex-dependent traits rather than differences in disease status. Our results demonstrated that sex differences are present in OA-affected tissues. Not only were there differences in the composition of synovial fluid between the sexes, but chondrocytes and osteoblasts isolated from OA-affected cartilage and bone differed in a sex-dependent manner with respect to expression of hormone receptors and responded differentially to 1α,25(OH)2D3, 24R,25(OH)2D3, E2, and DHT. Moreover, articular chondrocytes from men and women patients exhibited sex differences in their expression of genes for inflammatory cytokines, enzymes involved in matrix degradation, and WNT signaling molecules involved in regulation of proliferation and differentiation.

Our patient population exhibited few clinical differences between men and women. There was no evidence of a difference in serum 25(OH)D3 levels, radiographic assessment, knee pain, or areas of knee pain prior to surgery between women and men. This could be due to the advanced stage of disease in our study population. Studies of younger patients have shown sex differences in knees with OA, with articular cartilage surface areas being 17.5 % to 23.5 % lower in women than in men [36], which supports the idea that sex differences contribute to disease progression, but once the advanced disease is established, sex differences are less important.

We did observe some clinical differences in the study patient population that were sex dependent. The pain-pressure threshold 1 cm above the medial joint line was lower in women than in men; however, the clinical significance of this is unclear. We did not test the pain-pressure threshold of anatomic regions outside the medial knee, and further study is warranted. We also found that women were more likely to have used or were using vitamin D and estrogen supplements compared with men. Studies have linked estrogen supplementation with reduced risk of OA, which could explain how a drop in estrogen in postmenopausal women could contribute to the severity of OA found in women [8, 37, 38] compared with males. Together, these data suggest that future studies should include younger postmenopausal women and age-matched men to better assess sex differences in their disease severity.

The synovial fluid composition was affected by the genetic sex of the patient in a number of ways. Men had higher levels of MMPs, the primary enzymes responsible for the degradation of cartilage, and HGF, which is synthesized by osteoblasts from the subchondral bone plate and produced at a higher rate by OA osteoblasts [39]. However, men had higher levels of growth factors, including TGFβs, SCF (stem cell factor), and SCGFβ (stem cell growth factor beta), and sGAGs compared with females, which have been shown to protect articular cartilage from degradation [4042]. These results suggest that men may be more resistant to OA; although men had higher levels of matrix degradation enzymes, they also had more protective and growth-inducing factors that could aid in the repair and remodeling processes. Women had higher levels of inflammatory cytokines, especially IL18, which induces the production of PGE2 [43]. This is corroborated by studies showing that women experience more pain [6]. Women had less protective factors, which could explain their increased disease severity as they lose the protective effect of estrogen after menopause.

Vitamin D metabolites play important roles in skeletal development [44] and in maintaining cartilage and bone homeostasis [45, 46]. The ELISA kit used to measure 1,25(OH)2D3, a metabolite of 25(OH)D3 associated with Ca++ homeostasis as well as terminal differentiation of chondrocytes and osteoblasts [4749], did not detect a difference in the synovial fluid levels between men and women. Because a suitable kit does not exist for measuring 24,25(OH)2D3, a metabolite associated with chondrocyte proliferation and resistance to apoptotic stimuli [50], we compared results using two kits, one that measured 25(OH)D3 alone and one that measured 25(OH)D3, 25(OH)D2, and 24,25(OH)2D3. Both kits identified reduced vitamin D metabolites in female synovial fluid, suggesting a possible reduction in 24,25(OH)2D3. However, when 24,25(OH)2D3 was measured directly by a commercial lab using mass spectroscopy, no sex difference was found. None of these methods is definitive, but taken together, they show a clear and reproducible finding that synovial vitamin D metabolites are regulated in a sex-dependent manner.

Studies using growth plate chondrocytes and healthy human articular chondrocytes have shown that the numbers of receptors vary in a sex-specific manner [11, 29, 51]. Our results examining gene expression also demonstrated sex-dependent differences. Chondrocytes from male erosion tissue and minimally fibrillated tissue expressed higher levels of mRNAs for the nuclear VDR whereas receptors for ERα66 (ESR1) were lower in cells from male erosion tissue than from female erosion tissue. Osteoblasts from male erosion tissue subchondral bone exhibited higher nuclear VDR expression, and female osteoblasts had higher ESR1 than male cells. We also found that male chondrocytes and osteoblasts were more responsive to 1α,25(OH)2D3 treatment than female cells. Previously, studies have shown that male osteoblasts have a more robust response to 1α,25(OH)2D3 [52], which supports our findings. Female cells were more responsive to estrogen treatment compared with male cells, which is supported by their greater expression of estrogen receptor mRNAs. The study results are supported by our previous observations using articular chondrocytes from young healthy men without OA, which showed that male cells had no response to E2 whereas female chondrocytes exhibited a marked response to E2 [29]. Studies have shown that chondrogenic progenitor cells respond differently to estrogen and testosterone in repairing OA cartilage, suggesting sexual dimorphism exists in cell-repair mechanisms in OA [53]. Collectively, our data suggest that the difference in the levels of VDR and PDIA3 and local and circulating 25(OH)D3 between men and women, could contribute to the more prevalent and severe cases of OA found in women.

Chondrocytes isolated from both erosion cartilage and minimally fibrillated cartilage exhibited sex-specific phenotypic traits. In addition to differences in receptor expression, there were a number of differences with respect to expression of mRNAs for pro-inflammatory cytokines. The level of these cytokines was comparable for eroded cartilage cells regardless of sex; however, in minimally fibrillated cartilage cells, women had higher levels of pro-inflammatory cytokines compared with men. This suggests that female chondrocytes may produce higher levels of inflammatory cytokines at an earlier stage of OA. Interestingly, the anti-inflammatory cytokine IL10 was expressed at comparable levels in cells from men and women irrespective of tissue source.

Expression of mRNAs for WNT family genes varied in a sex-specific manner as well, but the interpretation of these data will require further experimentation. Higher levels of WNT antagonists are suggested to inhibit chondrocyte hypertrophy. DKK1 inhibits MMP-13 and ADAMTS-4 expression in chondrocytes in response to WNT3a treatment [54]. Activation of WNT/β-catenin signaling in primary human chondrocytes inhibits basal IL1β-stimulated increases in MMP-1, -3, and -13 levels, possibly through inhibition of NFκB signaling [55, 56]. Men had higher levels of WNT signaling molecules, which is consistent with our findings that although men had higher levels of MMPs, they may be more resistant to OA as they also had more factors that are protective.

The underlying etiology of OA is not well understood. It has been hypothesized that mechanical instabilities lead to changes in the biomechanical properties of the articular cartilage and, ultimately, in the biochemical properties of the cells and extracellular matrix [7]. Recent data indicate that there are sex-specific differences at the molecular and cellular level that may exacerbate the effects of altered mechanical load [5760]. Our data do not address disease etiology. While they do support the hypothesis that sex differences exist, all patients had advanced OA. Thus, it is not possible to attribute specific differences to a clinical outcome. It is possible, however, that sex differences may have contributed to differences in disease progression that led to the need for TKA.

This study had a number of limitations. We used passage 1 cells in our study to investigate the effect of hormone treatments on the cells. Human chondrocytes lose phenotypic traits when subpassaged, so it is preferable to use primary cells. Unfortunately, the number of primary cells was limited, necessitating the need for culture expansion. In a series of preliminary studies, we found that the first-passage cells expressed similar levels of chondrocyte and osteoblast markers to primary cells (data not shown). One of the limitations of our studies is that we could not get tissues from healthy human knees as a control; however, we addressed the limitation by using cartilage and subchondral bone from areas that showed minimal articular fibrillation.

Conclusions

In this study, we identified sex-specific differences in synovial fluid, chondrocytes, and osteoblasts in advanced human knee OA tissues. Our understanding of such sex-specific differences is still very early, and additional research is needed. Understanding such sex differences in knee OA may allow for the introduction of sex-specific therapies and new treatment avenues for patients experiencing this often disabling condition.

Abbreviations

sGAG: 

sulfated glycosaminoglycan

E2: 

17β-estradiol

DHT: 

dihydrotestosterone

1α,25(OH)2D3

1-alpha,25-dihydroxyvitamin D3

24R,25(OH)2D3

24R,25-dihydroxyvitamin D3

VDR: 

canonical vitamin D receptor

PDIA3: 

protein disulfide isomerase family A member 3

ERα66: 

canonical estrogen receptor a

ERα36: 

shorter variant estrogen receptor

OA: 

osteoarthritis

HGF: 

hepatocyte growth factor

SCF: 

stem cell factor

SCGFβ: 

stem cell growth factor beta

TGFβ: 

transforming growth factor beta

TNFα and TNFβ: 

tumor necrosis factor alpha and beta

MIF: 

macrophage migration inhibitory factor

WNT: 

wingless-related integrated site a family of signaling molecules

DKK1: 

Dickkopf-1

IL1α etc.: 

interleukin-1 alpha

ACAN: 

mRNA for aggrecan

COL2A1: 

mRNA for type-II collagen alpha 1 chain

COMP: 

mRNA for cartilage oligomeric matrix protein

MMP: 

matrix metalloproteinase

TRAIL: 

TNF-related apoptosis-inducing ligand

LIF: 

leukemia inhibitory factor

M-CSF: 

macrophage colony-stimulating factor

GRO-α: 

growth-regulated oncogene α

MCP-3: 

monocyte chemotactic protein-3

MIG: 

monokine induced by gamma interferon

CTNNB: 

mRNA for beta-catenin

TKA: 

total knee arthroplasty

SF-12: 

Short Form-12 Health Survey

WOMAC: 

Western Ontario & McMaster Universities Arthritis Index

PASE: 

Physical Activity Scale for the Elderly

OARSI-OMERACT: 

Osteoarthritis Research Society International-Outcome Measures in Rheumatology pain scale

Declarations

Acknowledgements

We thank Colleen Thomas at Mayo Clinic with help on statistical analyses of the clinical data. We also thank Dr. David Hart (University of Calgary) and Dr. Karen Berkley (Florida State University) for their contributions to the design of the studies. This work was supported by a grant from the Society for Women’s Health Research ISIS Network for Musculoskeletal Health and funding from Children’s Healthcare of Atlanta, the Price Gilbert, Jr. Foundation, the US Department of Defense, and the National Institutes of Health.

Authors’ contributions

This work represents partial completion of the PhD thesis for QP. QP and RON performed the cell culture assays; SLH catalogued all samples and assisted in the data analysis; QP wrote the original draft of the manuscript; MIO performed all clinical assessments and surgeries; RDC performed a review of the clinical data; BDB and ZS analyzed the results; BDB, ZS, and MIO edited the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Mechanical Engineering, Georgia Institute of Technology
(2)
Center for Musculoskeletal Care, Yale University School of Medicine
(3)
Department of Orthopaedics, University of California at San Diego
(4)
Department of Biomedical Engineering, Virginia Commonwealth University
(5)
Department of Periodontics, University of Texas Health Science Center at San Antonio
(6)
Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology
(7)
School of Engineering, Virginia Commonwealth University

References

  1. Murphy L, Schwartz TA, Helmick CG, Renner JB, Tudor G, Koch G, et al. Lifetime risk of symptomatic knee osteoarthritis. Arthritis Rheum. 2008;59:1207–13.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Valderrabano V, Steiger C. Treatment and prevention of osteoarthritis through exercise and sports. J Aging Res. 2010;2011:374653.PubMedPubMed CentralGoogle Scholar
  3. Richette P, Corvol M, Bardin T. Estrogens, cartilage, and osteoarthritis. Joint Bone Spine. 2003;70:257–62.View ArticlePubMedGoogle Scholar
  4. Bay-Jensen AC, Slagboom E, Chen-An P, Alexandersen P, Qvist P, Christiansen C, et al. Role of hormones in cartilage and joint metabolism: understanding an unhealthy metabolic phenotype in osteoarthritis. Menopause. 2013;20:578–86.PubMedGoogle Scholar
  5. Theis KA, Helmick CG, Hootman JM. Arthritis burden and impact are greater among U.S. women than men: intervention opportunities. J Womens Health (Larchmt). 2007;16:441–53.View ArticleGoogle Scholar
  6. Sluka KA, Berkley KJ, O'Connor MI, Nicolella DP, Enoka RM, Boyan BD, et al. Neural and psychosocial contributions to sex differences in knee osteoarthritic pain. Biol Sex Differ. 2012;3:26,6410-3-26.View ArticleGoogle Scholar
  7. Nicolella DP, O'Connor MI, Enoka RM, Boyan BD, Hart DA, Resnick E, et al. Mechanical contributors to sex differences in idiopathic knee osteoarthritis. Biol Sex Differ. 2012;3:28,6410-3-28.View ArticleGoogle Scholar
  8. Ham KD, Loeser RF, Lindgren BR, Carlson CS. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum. 2002;46:1956–64.View ArticlePubMedGoogle Scholar
  9. Ma HL, Blanchet TJ, Peluso D, Hopkins B, Morris EA, Glasson SS. Osteoarthritis severity is sex dependent in a surgical mouse model. Osteoarthritis Cartilage. 2007;15:695–700.View ArticlePubMedGoogle Scholar
  10. Ekstein J, Nasatzky E, Boyan BD, Ornoy A, Schwartz Z. Growth-plate chondrocytes respond to 17beta-estradiol with sex-specific increases in IP3 and intracellular calcium ion signalling via a capacitative entry mechanism. Steroids. 2005;70:775–86.View ArticlePubMedGoogle Scholar
  11. Elbaradie K, Wang Y, Boyan BD, Schwartz Z. Rapid membrane responses to dihydrotestosterone are sex dependent in growth plate chondrocytes. J Steroid Biochem Mol Biol. 2012;132:15-23.Google Scholar
  12. Sylvia VL, Hughes T, Dean DD, Boyan BD, Schwartz Z. 17beta-estradiol regulation of protein kinase C activity in chondrocytes is sex-dependent and involves nongenomic mechanisms. J Cell Physiol. 1998;176:435–44.View ArticlePubMedGoogle Scholar
  13. Ornoy A, Suissa M, Yaffe P, Boyan BD, Schwartz Z. Gender-related effects of vitamin D metabolites on cartilage and bone. Bone Miner. 1994;27:235–47.View ArticlePubMedGoogle Scholar
  14. Schwartz Z, Finer Y, Nasatzky E, Soskolne WA, Dean DD, Boyan BD, et al. The effects of 17 beta-estradiol on chondrocyte differentiation are modulated by vitamin D3 metabolites. Endocrine. 1997;7:209–18.View ArticlePubMedGoogle Scholar
  15. Olivares-Navarrete R, Hyzy SL, Chaudhri RA, Zhao G, Boyan BD, Schwartz Z. Sex dependent regulation of osteoblast response to implant surface properties by systemic hormones. Biol Sex Differ. 2010;1:4.View ArticlePubMedPubMed CentralGoogle Scholar
  16. Bouillon R, Suda T. Vitamin D: calcium and bone homeostasis during evolution. Bonekey Rep. 2014;3:480.View ArticlePubMedPubMed CentralGoogle Scholar
  17. St-Arnaud R. The direct role of vitamin D on bone homeostasis. Arch Biochem Biophys. 2008;473:225–30.View ArticlePubMedGoogle Scholar
  18. Ornoy A, Goodwin D, Noff D, Edelstein S. 24, 25-dihydroxyvitamin D is a metabolite of vitamin D essential for bone formation. Nature. 1978;276:517–9.View ArticlePubMedGoogle Scholar
  19. St-Arnaud R, Naja RP. Vitamin D metabolism, cartilage and bone fracture repair. Mol Cell Endocrinol. 2011;347:48–54.View ArticlePubMedGoogle Scholar
  20. Holick MF. Vitamin D, deficiency. N Engl J Med. 2007;357:266–81.View ArticlePubMedGoogle Scholar
  21. Felson DT, Niu J, Clancy M, Aliabadi P, Sack B, Guermazi A, et al. Low levels of vitamin D and worsening of knee osteoarthritis: results of two longitudinal studies. Arthritis Rheum. 2007;56:129–36.View ArticlePubMedGoogle Scholar
  22. Castillo EC, Hernandez-Cueto MA, Vega-Lopez MA, Lavalle C, Kouri JB, Ortiz-Navarrete V. Effects of Vitamin D Supplementation during the Induction and Progression of Osteoarthritis in a Rat Model. Evid Based Complement Alternat Med. 2012;2012:156563.View ArticlePubMedPubMed CentralGoogle Scholar
  23. Sylvia VL, Gay I, Hardin R, Dean DD, Boyan BD, Schwartz Z. Rat costochondral chondrocytes produce 17beta-estradiol and regulate its production by 1alpha,25(OH)(2)D(3). Bone. 2002;30:57–63.View ArticlePubMedGoogle Scholar
  24. Hawker GA, Davis AM, French MR, Cibere J, Jordan JM, March L, et al. Development and preliminary psychometric testing of a new OA pain measure—an OARSI/OMERACT initiative. Osteoarthritis Cartilage. 2008;16:409–14.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Thompson LR, Boudreau R, Hannon MJ, Newman AB, Chu CR, Jansen M, et al. The knee pain map: reliability of a method to identify knee pain location and pattern. Arthritis Rheum. 2009;61:725–31.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Vance CG, Rakel BA, Blodgett NP, DeSantana JM, Amendola A, Zimmerman MB, et al. Effects of transcutaneous electrical nerve stimulation on pain, pain sensitivity, and function in people with knee osteoarthritis: a randomized controlled trial. Phys Ther. 2012;92:898–910.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Rakel BA, Blodgett NP, Bridget Zimmerman M, Logsden-Sackett N, Clark C, Noiseux N, et al. Predictors of postoperative movement and resting pain following total knee replacement. Pain. 2012;153:2192–203.View ArticlePubMedPubMed CentralGoogle Scholar
  28. Goldberg RL, Kolibas LM. An improved method for determining proteoglycans synthesized by chondrocytes in culture. Connect Tissue Res. 1990;24:265–75.View ArticlePubMedGoogle Scholar
  29. Kinney RC, Schwartz Z, Week K, Lotz MK, Boyan BD. Human articular chondrocytes exhibit sexual dimorphism in their responses to 17beta-estradiol. Osteoarthritis Cartilage. 2005;13:330–7.View ArticlePubMedGoogle Scholar
  30. Chaudhri RA, Olivares-Navarrete R, Cuenca N, Hadadi A, Boyan BD, Schwartz Z. Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells via estrogen receptor-alpha36 (ERalpha36). J Biol Chem. 2012;287:7169-81.Google Scholar
  31. Hyzy SL, Olivares-Navarrete R, Hutton DL, Tan C, Boyan BD, Schwartz Z. Microstructured titanium regulates interleukin production by osteoblasts, an effect modulated by exogenous BMP-2. Acta Biomater. 2013;9:5821–9.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Olivares-Navarrete R, Hyzy SL, Park JH, Dunn GR, Haithcock DA, Wasilewski CE, et al. Mediation of osteogenic differentiation of human mesenchymal stem cells on titanium surfaces by a Wnt-integrin feedback loop. Biomaterials. 2011;32:6399–411.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Walker JM. The bicinchoninic acid (BCA) assay for protein quantitation. Methods Mol Biol. 1994;32:5–8.PubMedGoogle Scholar
  34. Olivares-Navarrete R, Gittens RA, Schneider JM, Hyzy SL, Haithcock DA, Ullrich PF, et al. Osteoblasts exhibit a more differentiated phenotype and increased bone morphogenetic protein production on titanium alloy substrates than on poly-ether-ether-ketone. Spine J. 2012;12:265–72.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Olivares-Navarrete R, Hyzy SL, Pan Q, Dunn G, Williams JK, Schwartz Z, et al. Osteoblast maturation on microtextured titanium involves paracrine regulation of bone morphogenetic protein signaling. J Biomed Mater Res A. 2015;103:1721–31.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Eckstein F, Siedek V, Glaser C, Al-Ali D, Englmeier KH, Reiser M, et al. Correlation and sex differences between ankle and knee cartilage morphology determined by quantitative magnetic resonance imaging. Ann Rheum Dis. 2004;63:1490–5.View ArticlePubMedPubMed CentralGoogle Scholar
  37. Spector TD, Nandra D, Hart DJ, Doyle DV. Is hormone replacement therapy protective for hand and knee osteoarthritis in women?: The Chingford Study. Ann Rheum Dis. 1997;56:432–4.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Roman-Blas JA, Castaneda S, Largo R, Herrero-Beaumont G. Osteoarthritis associated with estrogen deficiency. Arthritis Res Ther. 2009;11:241.View ArticlePubMedPubMed CentralGoogle Scholar
  39. Guevremont M, Martel-Pelletier J, Massicotte F, Tardif G, Pelletier JP, Ranger P, et al. Human adult chondrocytes express hepatocyte growth factor (HGF) isoforms but not HgF: potential implication of osteoblasts on the presence of HGF in cartilage. J Bone Miner Res. 2003;18:1073–81.View ArticlePubMedGoogle Scholar
  40. van Beuningen HM, van der Kraan PM, Arntz OJ, van den Berg WB. Does TGF-beta protect articular cartilage in vivo? Agents Actions Suppl. 1993;39:127–31.PubMedGoogle Scholar
  41. Hannan N, Ghosh P, Bellenger C, Taylor T. Systemic administration of glycosaminoglycan polysulphate (arteparon) provides partial protection of articular cartilage from damage produced by meniscectomy in the canine. J Orthop Res. 1987;5:47–59.View ArticlePubMedGoogle Scholar
  42. Man C, Zhu S, Zhang B, Hu J. Protection of articular cartilage from degeneration by injection of transforming growth factor-beta in temporomandibular joint osteoarthritis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;108:335–40.View ArticlePubMedGoogle Scholar
  43. Futani H, Okayama A, Matsui K, Kashiwamura S, Sasaki T, Hada T, et al. Relation between interleukin-18 and PGE2 in synovial fluid of osteoarthritis: a potential therapeutic target of cartilage degradation. J Immunother. 2002;25 Suppl 1:S61–4.View ArticlePubMedGoogle Scholar
  44. Idelevich A, Kerschnitzki M, Shahar R, Monsonego-Ornan E. 1,25(OH)2D3 alters growth plate maturation and bone architecture in young rats with normal renal function. PLoS One. 2011;6, e20772.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Ding C, Cicuttini F, Parameswaran V, Burgess J, Quinn S, Jones G. Serum levels of vitamin D, sunlight exposure, and knee cartilage loss in older adults: the Tasmanian older adult cohort study. Arthritis Rheum. 2009;60:1381–9.View ArticlePubMedGoogle Scholar
  46. Klaus G, Meinhold-Heerlein R, Milde P, Ritz E, Mehls O. Effect of vitamin D on growth cartilage cell proliferation in vitro. Pediatr Nephrol. 1991;5:461–6.View ArticlePubMedGoogle Scholar
  47. Boyan BD, Schwartz Z, Swain LD. In vitro studies on the regulation of endochondral ossification by vitamin D. Crit Rev Oral Biol Med. 1992;3:15–30.PubMedGoogle Scholar
  48. Boyan BD, Sylvia VL, Dean DD, Del Toro F, Schwartz Z. Differential regulation of growth plate chondrocytes by 1alpha,25-(OH)2D3 and 24R,25-(OH)2D3 involves cell-maturation-specific membrane-receptor-activated phospholipid metabolism. Crit Rev Oral Biol Med. 2002;13:143–54.View ArticlePubMedGoogle Scholar
  49. Myrtle JF, Norman AW. Vitamin D: A cholecalciferol metabolite highly active in promoting intestinal calcium transport. Science. 1971;171:79–82.View ArticlePubMedGoogle Scholar
  50. Boyan BD, Hurst-Kennedy J, Denison TA, Schwartz Z. 24R,25-dihydroxyvitamin D3 [24R,25(OH)2D3] controls growth plate development by inhibiting apoptosis in the reserve zone and stimulating response to 1alpha,25(OH)2D3 in hypertrophic cells. J Steroid Biochem Mol Biol. 2010;121:212–6.View ArticlePubMedGoogle Scholar
  51. McMillan J, Fatehi-Sedeh S, Sylvia VL, Bingham V, Zhong M, Boyan BD, et al. Sex-specific regulation of growth plate chondrocytes by estrogen is via multiple MAP kinase signaling pathways. Biochim Biophys Acta. 2006;1763:381–92.View ArticlePubMedGoogle Scholar
  52. Chen J, Olivares-Navarrete R, Wang Y, Herman TR, Boyan BD, Schwartz Z. Protein-disulfide isomerase-associated 3 (Pdia3) mediates the membrane response to 1,25-dihydroxyvitamin D3 in osteoblasts. J Biol Chem. 2010;285:37041–50.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Koelling S, Miosge N. Sex differences of chondrogenic progenitor cells in late stages of osteoarthritis. Arthritis Rheum. 2010;62:1077–87.View ArticlePubMedGoogle Scholar
  54. Oh H, Chun CH, Chun JS. Dkk-1 expression in chondrocytes inhibits experimental osteoarthritic cartilage destruction in mice. Arthritis Rheum. 2012;64:2568–78.View ArticlePubMedGoogle Scholar
  55. Bougault C, Priam S, Houard X, Pigenet A, Sudre L, Lories RJ, et al. Protective role of frizzled-related protein B on matrix metalloproteinase induction in mouse chondrocytes. Arthritis Res Ther. 2014;16:R137.View ArticlePubMedPubMed CentralGoogle Scholar
  56. Leijten JC, Bos SD, Landman EB, Georgi N, Jahr H, Meulenbelt I, et al. GREM1, FRZB and DKK1 mRNA levels correlate with osteoarthritis and are regulated by osteoarthritis-associated factors. Arthritis Res Ther. 2013;15:R126.View ArticlePubMedPubMed CentralGoogle Scholar
  57. Boyan BD, Hart DA, Enoka RM, Nicolella DP, Resnick E, Berkley KJ, et al. Hormonal modulation of connective tissue homeostasis and sex differences in risk for osteoarthritis of the knee. Biol Sex Differ. 2013;4:3,6410-4-3.Google Scholar
  58. Lang TF. The bone-muscle relationship in men and women. J Osteoporos. 2011;2011:702735.View ArticlePubMedPubMed CentralGoogle Scholar
  59. Clark AL, Votta BJ, Kumar S, Liedtke W, Guilak F. Chondroprotective role of the osmotically sensitive ion channel transient receptor potential vanilloid 4: age- and sex-dependent progression of osteoarthritis in Trpv4-deficient mice. Arthritis Rheum. 2010;62:2973–83.View ArticlePubMedPubMed CentralGoogle Scholar
  60. Li ZC, Dai LY, Jiang LS, Qiu S. Difference in subchondral cancellous bone between postmenopausal women with hip osteoarthritis and osteoporotic fracture: implication for fatigue microdamage, bone microarchitecture, and biomechanical properties. Arthritis Rheum. 2012;64:3955–62.View ArticlePubMedGoogle Scholar

Copyright

© Pan et al. 2016

Advertisement